The 16th International Symposium on Translational Research in Oncology, Sept 27th-29th, 2023, Herbert Park Hotel, Dublin 4

To Register for the 16th International Symposium on Translational Research in Oncology please click here

For printable version of programme please click here: 18.09.23 Programme – 16th International Symposium on Translational Research in Oncology

To register for the AICRI – Vision and Showcase event click here

16th International Symposium on Translational Research in Oncology


Wednesday, 27th September 2023, Lansdowne Suite 

09.00 – 12.30 AICRI Showcase To register for the AICRI showcase click here

Registration for the Symposium from 12:30                                CPD:3 external credits

13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital Group, Dublin

TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center

13:45 – 14:15 HER2 as a therapeutic target in HER2-normal breast cancer

Prof. Sara Hurvitz, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Head, Division of Hematology/Oncology, University of Washington

14:15 – 14:45 Targeting Estrogen Receptor in breast cancer: old target, new drugs

Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston

14:45 – 15:15 HER2+ GP2 vaccine and the FLAMINGO Phase III trial

Mr. Snehal Patel, CEO, Greenwich Lifesciences

15:15 – 15:30 Coffee break

TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center

15:30 – 16:15 Patient-derived models of breast cancer for drug discovery and precision medicine

Dr. Alana Welm, Huntsman Cancer Institute, University of Utah, Salt Lake City

16:15 – 16:45 TPD squared – Dual-Precision Targeted Protein Degradation For Oncology Therapeutics Discovery and Development

Dr. James Palacino, VP/Head of Biology, Orum Therapeutics


16:45 – 17:15 Topic: CDK inhibitors and the NATALEE trial

Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology UCLA.


Thursday, 28th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30                                                     CPD:  6 external credits

TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto

09:00 – 09:30 Modulation of the tumor associated fibronectin ECM to enhance efficacy of immune checkpoint blockade

Prof Robert Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute, University of Toronto

09:30 – 10:00 Overcoming endothelial cell anergy for improvement of immunotherapy against cancer

Prof Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC

10:00 – 10:30 Orally available RGD-mimetic and enhancement of immunotherapy efficacy

Prof Kairbaan Hodivala Dilke, Professor of Tumour Microenvironment, Queen Mary University of London, and Deputy Director of Barts Cancer Institute.

10:30 – 10:45        Coffee break

TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto

10:45 – 11:15 Brain metastasis in the era of immunotherapy: implications for sequential immunotherapy-based combination therapy

Prof Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center

 11.15 – 11:45 Control of malignant properties by functionally and spatially distinct cancer-associated fibroblasts

Professor Kristian Pietras, Division of Translational Cancer Research, Lund University Cancer Centre

11:45 – 12:15    Extracellular Vesicles in the Tumour Microenvironment

Prof Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Sciences, Panoz Institute & Trinity Biomedical Sciences Institute & Research Director, Trinity St. James’s Cancer Institute, Trinity College Dublin


12:15 – 13:00    Normalizing the tumor microenvironment to improve immunotherapy of brain tumors: Emerging insights and strategies

Prof. Rakesh Jain, National Medal of Science Awardee 2013, Andrew Werk Cook Professor of Tumor Biology, Massachusetts General Hospital, Harvard Medical School & Director E.L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital.

13:00 – 14:00   Lunch

Targeting Difficult to Drug Genes for Cancer Therapy: Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin

14:00 – 14:30 Targeting MYC: A Dual Effect on Both Cancer Cells and Tumor Microenvironment

Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.

14:30 – 15:00   Biomarker driven development of Brigimadlin, a MDM2-p53 antagonist restoring p53 activity

Dr. Michael Teufel, Exec Dir Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim

15:00 – 15:30    Combination strategies to potentiate the impact of KRAS inhibitors

Dr. Miriam Molina-Arcas, Oncogene Biology Laboratory, The Francis Crick Institute

15:30 – 15:45  Coffee break

Novel Targeted therapies: Session Chair – Prof Denis Collins, Dublin City University

15:45 – 16.15        Development of a novel therapeutic mAb and ADC for CLDN18.2

Dr. Neil O’Brien, Adj Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA

16:15 – 16:45        Selective Therapies for Metastatic Tumor Cells

Prof Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology, Harvard

16:45 – 17:15  Evolving insights into biomarkers and treatment of hepatocellular carcinoma

Prof. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.

17:15 – 17:45   Development and characterisation of an anti-Claudin-6 (CLDN6) ADC for the treatment of CLDN6 positive cancer

Dr. Martina McDermott, Adj Assoc Prof, Dept of Medicine, Division of Hematology/Oncology, UCLA ______________________________________________________________

Friday 29th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 8:30                                                              CPD:  4 external credits

CANCER IMMUNOTHERAPY I – exploiting immune cells: Session Chair – Prof. Mario Sznol, Yale

09:00 – 09:30       DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates anti-tumor immunity

Dr. Michael Dougan, Massachusetts General Hospital, Harvard Medical School

09:30 – 10:00     Novel Biomarker Discovery for NX-1607: Clinical Insights into a First-in-Class Oral CBL-B Inhibitor for Advanced Malignancies

Dr. Sarah Whelan, Associate Director, Translational Medicine, Nurix Therapeutics   

10:00 – 10:30 ACTengine® IMA203 TCR-T: Unleashing the Potential of Targeting PRAME in Solid Tumors

Prof. Dr. med Oliver Ebert, Senior Director, Head of Clinical Development, Immatics

10:30 – 11:00       Cancer cell metabolomics and immunotherapy resistance

Prof.  Ken O’ Bryne, Professor of Medical Oncology, Queensland University of Technology

11:00 – 11:15       Coffee break

CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale

11:15-11:45   Cis-targeting of IL-2 and IL-21 cytokines to CD8+ T cells to improve immunotherapies for cancer

Dr. Ivana Djuretic, Chief Scientific Officer, Asher Biotherapeutics

11:45 – 12:15     Development of XTX301, a bioengineered masked, tumor-activated IL-12: unleashing the potent cytokine in the tumor microenvironment

Dr. Katarina Luptakova, MD, Senior Vice President, Medical, Xilio Therapeutics

12:15 – 12:45        New Strategies in Immuno-Oncology: Tumor-directed Oncolytic Immunotherapy (TOI)

Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune

12:45 – 13:00  Q & A

13:00 – 14:00     Lunch

Novel targeted drugs & biomarkers: Session Chair – Prof William Gallagher, University College Dublin

14:00 – 14:30   Cancer as a combinatorial challenge

Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program

14:30 – 15:00     Targeting mediator kinases in prostate and breast cancers

Prof Igor Roninson, CSO, Senex Biotechnology & Prof Eugenia Broude, University of South Carolina

15:00 – 15:30      The role of MRD detection and quantitation in solid tumors

Dr Minetta Liu, Chief Medical Officer, Natera

15:30 – 15:45       Coffee break

Novel targeted drugs & biomarkers II: Session Chair – Prof John Crown, St Vincent’s Hospital

15:45 – 16:15    Understanding TIL therapy for metastatic melanoma

Prof John Haanen, Medical Oncology Dept. Netherlands Cancer Institute

16:15 – 16:45    A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)

Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine

16:45 – 17:15  Topic: Fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma

Prof. John Crown, Consultant Medical Oncologist, St Vincent’s Hospital, Dublin; Professor of Oncology, University College Dublin; Thomas Baldwin Chair of Translational Oncology, Dublin City University

                         Meeting Ends